Novavax Inc (NVAX) outlines its strategic focus on partnerships and pipeline expansion while navigating revenue fluctuations ...

The US-developed NOVAVAX vaccine against COVID-19 has been approved Monday by the European Medicines Agency (EMA), thus becoming the fifth drug of its kind to become available at a continental level.

Transitioned lead commercial responsibility of Nuvaxovid COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in ...

Novavax’s COVID-19 vaccine produced higher levels of neutralising antibodies than produced by recovered patients in an early trial, paving the way for a phase 3 trial and potential approval by ...

There is no approved vaccine for C ... launch and long-term commitment to commercializing our COVID-19 vaccine. As a reminder, Novavax is eligible to receive royalties in the high-teens to ...

Novavax NVAX incurred a fourth-quarter ... A regulatory filing is currently under the FDA’s review seeking full approval for the COVID-19 vaccine, with a final decision expected in April.

Novavax has significantly reduced its net loss in the fourth quarter of 2024 to $81.03 million ($0.51 per share), a ...

Novavax Inc. shares climbed 2% on Wednesday and extended gains in after-hours trading, as retail investors maintained a ...

Late last week in Morbidity and Mortality Weekly Report, authors from the Centers for Disease Control and Prevention (CDC) ...

2, reflecting the shift of the COVID-19 vaccine category to annual ... A third player in the market, Novavax, filed for approval of a non-mRNA vaccine based on the earlier JN.